This research therefore underscores novel potential roles of MAP4K4 and SNO-Drp1 in DCM and suggests that MAP4K4 or SNO-Drp1 may be novel therapeutic targets for endothelial ferroptosis. Here, DNM1L is linked to familial dilated cardiomyopathy.